Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease

被引:30
|
作者
Yang, Yue [1 ]
Keene, C. Dirk [1 ]
Peskind, Elaine R. [2 ,3 ]
Galasko, Douglas R. [4 ]
Hu, Shu-Ching [5 ]
Cudaback, Eiron [1 ]
Wilson, Angela M. [1 ]
Li, Ge [2 ]
Yu, Chang-En [6 ,7 ]
Montine, Kathleen S. [1 ]
Zhang, Jing [1 ]
Baird, Geoffrey S. [1 ,8 ]
Hyman, Bradley T. [9 ]
Montine, Thomas J. [1 ]
机构
[1] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[3] VA Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA USA
[4] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[5] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
[6] Univ Washington, Dept Med, Seattle, WA 98195 USA
[7] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA
[8] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[9] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA
关键词
Alzheimer disease; Biomarkers; Cerebrospinal fluid; Cognitive impairment; Neurodegenerative disease; Parkinson disease; APOLIPOPROTEIN-A-I; AMYLOID PRECURSOR PROTEIN; MILD COGNITIVE IMPAIRMENT; GENOME-WIDE ASSOCIATION; CENTRAL-NERVOUS-SYSTEM; E APOE POLYMORPHISM; TARGETED REPLACEMENT; MEMBRANE-VESICLES; MOUSE MODEL; CIRCULATING MICROPARTICLES;
D O I
10.1097/NEN.0000000000000207
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Human cerebrospinal fluid (CSF) contains diverse lipid particles, including lipoproteins that are distinct from their plasma counterparts and contain apolipoprotein (apo) E isoforms, apoJ, and apoAI, and extracellular vesicles, which can be detected by annexin V binding. The aim of this study was to develop a method to quantify CSF particles and evaluate their relationship to aging and neurodegenerative diseases. We used a flow cytometric assay to detect annexin V-, apoE-, apoAI-, apoJ-, and amyloid (A) (42)-positive particles in CSF from 131 research volunteers who were neurologically normal or had mild cognitive impairment (MCI), Alzheimer disease (AD) dementia, or Parkinson disease. APOE epsilon 4/epsilon 4 participants had CSF apoE-positive particles that were more frequently larger but at an 88% lower level versus those in APOE epsilon 3/epsilon 3 or APOE epsilon 3/epsilon 4 patients; this finding was reproduced in conditioned medium from mouse primary glial cell cultures with targeted replacement of apoE. Cerebrospinal fluid apoE-positive and -amyloid (A(42))-positive particle concentrations were persistently reduced one-third to one-half in middle and older age subjects; apoAI-positive particle concentration progressively increased approximately 2-fold with age. Both apoAI-positive and annexin V-positive CSF particle levels were reduced one-third to one-half in CSF of MCI and/or AD dementia patients versus age-matched controls. Our approach provides new methods to investigate CNS lipid biology in relation to neurodegeneration and perhaps develop new biomarkers for diagnosis or treatment monitoring.
引用
收藏
页码:672 / 687
页数:16
相关论文
共 50 条
  • [21] Alzheimer disease pathology and the cerebrospinal fluid proteome
    Dayon, Loic
    Galindo, Antonio Nunez
    Wojcik, Jerome
    Cominetti, Ornella
    Corthesy, John
    Oikonomidi, Aikaterini
    Henry, Hugues
    Kussmann, Martin
    Migliavacca, Eugenia
    Severin, India
    Bowman, Gene L.
    Popp, Julius
    ALZHEIMERS RESEARCH & THERAPY, 2018, 10
  • [22] Cerebrospinal fluid biomarkers of Alzheimer's disease
    Xiaojing Sui
    Jianjun Liu
    Xifei Yang
    Neuroscience Bulletin, 2014, 30 (02) : 233 - 242
  • [23] Protein τ in cerebrospinal fluid of patients with Alzheimer disease
    Franciotta, D
    Di Paolo, E
    Tinelli, C
    d'Eril, GM
    CLINICAL CHEMISTRY, 1998, 44 (02) : 357 - 358
  • [24] Cerebrospinal fluid opens a window on Alzheimer disease
    Galasko, D
    ARCHIVES OF NEUROLOGY, 1999, 56 (06) : 655 - 656
  • [25] Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy
    Konings, CH
    Kuiper, MA
    Teerlink, T
    Mulder, C
    Schltens, P
    Wolters, EC
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 168 (02) : 112 - 115
  • [26] Cerebrospinal fluid biomarkers in Alzheimer's disease, Parkinson's disease and atypical parkinsonism in a Serbian group of patients
    Stojmenovic, G. Mandic
    Markovic, I.
    Stojkovic, T.
    Despotovic, I.
    Lukic, M. Jecmenica
    Stefanova, E.
    Kostic, V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 472 - 472
  • [27] Altered Cerebrospinal Fluid Levels of α-Synuclein and Aβ in Parkinson Disease
    Kotzbauer, Paul T.
    Buddhala, Chandana
    Campbell, Meghan C.
    Perlmutter, Joel S.
    ANNALS OF NEUROLOGY, 2013, 74 : S42 - S42
  • [28] Cerebrospinal Fluid Biomarkers for Parkinson Disease Diagnosis and Progression
    Shi, Min
    Bradner, Joshua
    Hancock, Aneeka M.
    Chung, Kathryn A.
    Quinn, Joseph F.
    Peskind, Elaine R.
    Galasko, Douglas
    Jankovic, Joseph
    Zabetian, Cyrus P.
    Kim, Hojoong M.
    Leverenz, James B.
    Montine, Thomas J.
    Ginghina, Carmen
    Kang, Un Jung
    Cain, Kevin C.
    Wang, Yu
    Aasly, Jan
    Goldstein, David
    Zhang, Jing
    ANNALS OF NEUROLOGY, 2011, 69 (03) : 570 - 580
  • [29] Cerebrospinal fluid protein biomarkers in Parkinson's disease
    Faizan, Mohd
    Sachan, Nidhi
    Verma, Oyashvi
    Sarkar, Alika
    Rawat, Neeraj
    Singh, Mahendra Pratap
    CLINICA CHIMICA ACTA, 2024, 556
  • [30] Cerebrospinal fluid orexin and sleep attacks in Parkinson disease
    Asai, Hirohide
    Hirano, Makito
    Furiya, Yoshiko
    Kanbayashi, Takashi
    Ikeda, Masanori
    Kiriyama, Takao
    Ueno, Satoshi
    ANNALS OF NEUROLOGY, 2008, 64 : S50 - S51